Spironolactone treatment resulted in marked improvement of paralytic symptoms in a patient with familial hypokalemic periodic paralysis caused by a rare R1239G mutation in the CACNA1S gene.
No takes yet. Share an insight, caveat, or question.
May support spironolactone trial for rapid relief in rare CACNA1S hypokalemic periodic paralysis; single case leaves open need for controlled validation.
Kim et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: